Sunesis Seeks OK for Cancer Drug Trial
Posted on: Thursday, 1 March 2007, 12:01 CST
Sunesis said Thursday it filed an investigational new drug application with the U.S. Food and Drug Administration for its anti-cancer agent SNS-314.
The compound inhibits Aurora kinases, which are enzymes involved in cancer cell growth and division.
With SNS-314, we have observed robust, dose-dependent activity under multiple dosing schedules, which should provide greater dosing flexibility in the clinic than competitor candidates, said Daniel Adelman, Sunesis' senior vice president of research and development.
In our first phase 1 study, we plan to dose SNS-314 intravenously on a weekly basis, Adelman added.
Daniel Swisher, Sunesis' chief executive officer and president, said the company anticipates initiating a clinical trial involving patients with advanced solid tumors in the second quarter.
Source: United Press International
Related Articles
- Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
- Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
- Sunesis Pharmaceuticals and the Multiple Myeloma Research Consortium Form Collaboration to Study SNS-032 in Multiple Myeloma
- Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
- Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
- Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
- Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595
- Sunesis Presents Results From Phase I Clinical and Preclinical Studies of SNS-595 at American Association for Cancer Research Meeting
- Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Non-Small Cell Lung Cancer
- Sunesis Initiates Second Phase I Study of SNS-595 for Cancer
 |
 |
User Comments (0)
RSS Feeds